Based on the key indicators related to X4 Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, X4 Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, X4 Pharmaceuticals' Other Current Assets are relatively stable compared to the past year. As of 03/22/2025, Other Stockholder Equity is likely to grow to about 638.7 M, while Total Current Liabilities is likely to drop slightly above 13.7 M. Key indicators impacting X4 Pharmaceuticals' financial strength include:
Investors should never underestimate X4 Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor X4 Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in X4 Pharmaceuticals.
Net Income
(95.6 Million)
XFOR
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Cash Conversion Cycle
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Investments
Net Borrowings
Change To Operating Activities
Change To Netincome
Change To Liabilities
Dividends Paid
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Common Stock
Other Liab
Net Tangible Assets
Other Assets
Long Term Debt
Inventory
Short Long Term Debt
Non Current Liabilities Other
Property Plant Equipment
Long Term Debt Total
Capital Surpluse
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Net Interest Income
Gross Profit
Net Income From Continuing Ops
Cost Of Revenue
Reconciled Depreciation
Tax Provision
Probability Of Bankruptcy
Understanding current and past X4 Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of X4 Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in X4 Pharmaceuticals' assets may result in an increase in income on the income statement.
X4 Pharmaceuticals competes with Terns Pharmaceuticals, Day One, PDS Biotechnology, Inozyme Pharma, and Acumen Pharmaceuticals. X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. The company was founded in 2010 and is headquartered in Boston, Massachusetts. X4 Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 83 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what X4 Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining X4 Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare X4 Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across X4 Pharmaceuticals competition to find correlations between indicators driving X4 Pharmaceuticals's intrinsic value. More Info.
X4 Pharmaceuticals is rated second in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, X4 Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value X4 Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
X4 Pharmaceuticals Systematic Risk
X4 Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. X4 Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on X4 Pharmaceuticals correlated with the market. If Beta is less than 0 X4 Pharmaceuticals generally moves in the opposite direction as compared to the market. If X4 Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one X4 Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of X4 Pharmaceuticals is generally in the same direction as the market. If Beta > 1 X4 Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in X4 Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various X4 Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of X4 Pharmaceuticals growth as a starting point in their analysis.
X4 Pharmaceuticals March 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of X4 Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of X4 Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of X4 Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing XFOR Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build X4 Pharmaceuticals's daily price indicators and compare them against related drivers.
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.